Results for tag: "Androgenetic Alopecia"

Androgenetic alopecia, also known as male or female pattern hair loss, is a common form of hair loss affecting both men and women. Although not traditionally categorized as an immune disorder, recent research suggests that immune response may contribute to the pathophysiology of the condition. Immune disorders drugs pertain to therapies that modify or modulate the immune system, some of which have been found to incidentally affect hair growth. For example, drugs initially developed for autoimmune conditions have been observed to stimulate hair regrowth in some patients with alopecia. These observations have led to a growing interest in the potential repurposing of specific immune modulators for the treatment of androgenetic alopecia. The therapeutic approach typically targets immune pathways that may inadvertently suppress hair follicle activity, aiming to either inhibit or regulate immune responses. The therapeutic landscape for androgenetic alopecia within the context of immune disorders drugs includes both off-label use of existing immunomodulatory medications and the development of new therapies specifically geared towards treating hair loss. Some companies that are active in the androgenetic alopecia market include Pfizer, Johnson & Johnson, Merck & Co., and Aclaris Therapeutics. These companies may be involved in the production of existing treatments for androgenetic alopecia such as minoxidil and finasteride, or in the research and development of novel therapies that target the immune aspects of hair loss. The continued research and development in this space reflect an evolving understanding of the complex interactions between the immune Show Less Read more